Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT07515625 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07515625
Sponsor: Fudan University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Gastric Cancer (GC)AFP Gastric or Gastroesophageal Junction Adenocarcinoma

Start date: 2026-04-01
Primary completion: 2028-04-01
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.